Discovery of 3-(2,6-dichloro-3,5-dimethoxy-phenyl)-1-{6-[4-(4-ethyl-piperazin-1-yl)-phenylamino]-pyrimidin-4-yl}-1-methyl-urea (NVP-BGJ398), a potent and selective inhibitor of the fibroblast growth factor receptor family of receptor tyrosine kinase.
暂无分享,去创建一个
Pascal Furet | C. Schnell | J. Brueggen | P. Furet | M. Jensen | D. Bussiere | M. Wartmann | J. Murray | P. Drueckes | V. Guagnano | Markus Wartmann | Christian Schnell | Michael R Jensen | Diana Graus Porta | Christelle Stamm | Joerg Berghausen | Alfred Zimmerlin | Peter Drueckes | Jeremy Murray | A. Zimmerlin | C. Spanka | Josef Brueggen | Vito Guagnano | Carsten Spanka | Vincent Bordas | Mickaël Le Douget | Herbert Schmid | Dirksen Bussiere | C. Stamm | Diana Graus Porta | V. Bordas | J. Berghausen | Mickaël Le Douget | Herbert A. Schmid
[1] G. Martinelli,et al. Identification of four new translocations involving FGFR1 in myeloid disorders , 2001, Genes, chromosomes & cancer.
[2] D. Horsfall,et al. EMS1 amplification can occur independently of CCND1 or INT-2 amplification at 11q13 and may identify different phenotypes in primary breast cancer , 1997, Oncogene.
[3] D. Birnbaum,et al. Expression of the FGFR1 gene in human breast‐carcinoma cells , 1994, International journal of cancer.
[4] G. Borsani,et al. int‐2 Oncogene amplification and prognosis in node‐negative breast carcinoma , 1997, International journal of cancer.
[5] I. Petersen,et al. Frequent and Focal FGFR1 Amplification Associates with Therapeutically Tractable FGFR1 Dependency in Squamous Cell Lung Cancer , 2010, Science Translational Medicine.
[6] P. Furet,et al. Entry into a new class of protein kinase inhibitors by pseudo ring design. , 2008, Bioorganic & medicinal chemistry letters.
[7] M. Mohammadi,et al. The FGF family: biology, pathophysiology and therapy , 2009, Nature Reviews Drug Discovery.
[8] P. Pollock,et al. Frequent activating FGFR2 mutations in endometrial carcinomas parallel germline mutations associated with craniosynostosis and skeletal dysplasia syndromes , 2007, Oncogene.
[9] E. Schröck,et al. Frequent translocation t(4;14)(p16.3;q32.3) in multiple myeloma is associated with increased expression and activating mutations of fibroblast growth factor receptor 3 , 1997, Nature Genetics.
[10] S. Hubbard,et al. Crystal structure of an angiogenesis inhibitor bound to the FGF receptor tyrosine kinase domain , 1998, The EMBO journal.
[11] M. Rocchi,et al. A novel chromosomal translocation t(4; 14)(p16.3; q32) in multiple myeloma involves the fibroblast growth-factor receptor 3 gene. , 1997, Blood.
[12] J. Fargnoli,et al. Discovery and preclinical studies of (R)-1-(4-(4-fluoro-2-methyl-1H-indol-5-yloxy)-5- methylpyrrolo[2,1-f][1,2,4]triazin-6-yloxy)propan- 2-ol (BMS-540215), an in vivo active potent VEGFR-2 inhibitor. , 2006, Journal of medicinal chemistry.
[13] D. Oscier,et al. Identification of a novel gene, FGFR1OP2, fused to FGFR1 in 8p11 myeloproliferative syndrome , 2004, Genes, chromosomes & cancer.
[14] F. Bertucci,et al. Expression of fgf and fgf receptor genes in human breast cancer , 1995, International journal of cancer.
[15] D. Birnbaum,et al. Fibroblast growth factor receptor 1 is fused to FIM in stem-cell myeloproliferative disorder with t(8;13). , 1998, Proceedings of the National Academy of Sciences of the United States of America.
[16] M Taniwaki,et al. Fusion of ETV6 to fibroblast growth factor receptor 3 in peripheral T-cell lymphoma with a t(4;12)(p16;p13) chromosomal translocation. , 2001, Cancer research.
[17] Johanna M Jansen,et al. Design, structure-activity relationships and in vivo characterization of 4-amino-3-benzimidazol-2-ylhydroquinolin-2-ones: a novel class of receptor tyrosine kinase inhibitors. , 2009, Journal of medicinal chemistry.
[18] G Vriend,et al. WHAT IF: a molecular modeling and drug design program. , 1990, Journal of molecular graphics.
[19] J. Rubin,et al. Amplification of the Int-2 gene in head and neck squamous cell carcinoma , 1995, The Journal of Laryngology & Otology.
[20] D. Birnbaum,et al. BEK and FLG, two receptors to members of the FGF family, are amplified in subsets of human breast cancers. , 1991, Oncogene.
[21] S. Santa Cruz,et al. Fibroblast growth factor receptor 3 is overexpressed in urinary tract carcinomas and modulates the neoplastic cell growth. , 2005, Clinical cancer research : an official journal of the American Association for Cancer Research.
[22] Cem Elbi,et al. FGFR2-amplified gastric cancer cell lines require FGFR2 and Erbb3 signaling for growth and survival. , 2008, Cancer research.
[23] Alan Mackay,et al. FGFR1 Emerges as a Potential Therapeutic Target for Lobular Breast Carcinomas , 2006, Clinical Cancer Research.
[24] D. Chopin,et al. Frequent activating mutations of FGFR3 in human bladder and cervix carcinomas , 1999, Nature Genetics.
[25] D. Higgins,et al. T-Coffee: A novel method for fast and accurate multiple sequence alignment. , 2000, Journal of molecular biology.
[26] G. Mcmahon,et al. Design, synthesis, and evaluations of substituted 3-[(3- or 4-carboxyethylpyrrol-2-yl)methylidenyl]indolin-2-ones as inhibitors of VEGF, FGF, and PDGF receptor tyrosine kinases. , 1999, Journal of medicinal chemistry.
[27] R. V. van Etten,et al. Distinct stem cell myeloproliferative/T lymphoma syndromes induced by ZNF198-FGFR1 and BCR-FGFR1 fusion genes from 8p11 translocations. , 2004, Cancer cell.
[28] F. Hilberg,et al. Design, synthesis, and evaluation of indolinones as triple angiokinase inhibitors and the discovery of a highly specific 6-methoxycarbonyl-substituted indolinone (BIBF 1120). , 2009, Journal of medicinal chemistry.
[29] F. Lo‐Coco,et al. 8p11 myeloproliferative syndrome with a novel t(7;8) translocation leading to fusion of the FGFR1 and TIF1 genes , 2005, Genes, chromosomes & cancer.
[30] J. Partanen,et al. Amplification of fgfr4 gene in human breast and gynecological cancers , 1993, International journal of cancer.
[31] Wei-Sheng Huang,et al. Discovery of 3-[2-(imidazo[1,2-b]pyridazin-3-yl)ethynyl]-4-methyl-N-{4-[(4-methylpiperazin-1-yl)methyl]-3-(trifluoromethyl)phenyl}benzamide (AP24534), a potent, orally active pan-inhibitor of breakpoint cluster region-abelson (BCR-ABL) kinase including the T315I gatekeeper mutant. , 2010, Journal of medicinal chemistry.
[32] A. Bairoch,et al. The SWISS-PROT protein sequence data bank: current status. , 1994, Nucleic acids research.
[33] P. Sismondi,et al. FGFRI and PLAT genes and DNA amplification at 8p 12 in breast and ovarian cancers , 1993, Genes, chromosomes & cancer.
[34] C. Abbou,et al. Frequent FGFR3 mutations in papillary non-invasive bladder (pTa) tumors. , 2001, The American journal of pathology.
[35] Collaborative Computational,et al. The CCP4 suite: programs for protein crystallography. , 1994, Acta crystallographica. Section D, Biological crystallography.
[36] D. Xie,et al. Up-regulation of fibroblast growth factor 3 is associated with tumor metastasis and recurrence in human hepatocellular carcinoma. , 2007, Cancer letters.
[37] D. Fabbro,et al. PKC412 inhibits the zinc finger 198-fibroblast growth factor receptor 1 fusion tyrosine kinase and is active in treatment of stem cell myeloproliferative disorder. , 2004, Proceedings of the National Academy of Sciences of the United States of America.
[38] N. Turner,et al. Fibroblast growth factor signalling: from development to cancer , 2010, Nature Reviews Cancer.
[39] W. Denny,et al. Synthesis and Structure−Activity Relationships of Soluble 7-Substituted 3-(3,5-Dimethoxyphenyl)-1,6-naphthyridin-2-amines and Related Ureas as Dual Inhibitors of the Fibroblast Growth Factor Receptor-1 and Vascular Endothelial Growth Factor Receptor-2 Tyrosine Kinases , 2005 .
[40] Des Powe,et al. FGFR1 amplification in breast carcinomas: a chromogenic in situ hybridisation analysis , 2007, Breast Cancer Research.
[41] L. Baldini,et al. Analysis of FGFR3 gene mutations in multiple myeloma patients with t(4;14) , 2001, British journal of haematology.
[42] N. Saijo,et al. AZD2171 Shows Potent Antitumor Activity Against Gastric Cancer Over-Expressing Fibroblast Growth Factor Receptor 2/Keratinocyte Growth Factor Receptor , 2007, Clinical Cancer Research.
[43] J. Foekens,et al. Oncogene amplification and prognosis in breast cancer: relationship with systemic treatment. , 1995, Gene.
[44] J. Kodama,et al. Detection of c-erbB-2 and FGF-3 (INT-2) gene amplification in epithelial ovarian cancer. , 2000, International journal of oncology.
[45] J. G. Park,et al. Mutations in fibroblast growth factor receptor 2 and fibroblast growth factor receptor 3 genes associated with human gastric and colorectal cancers. , 2001, Cancer research.
[46] I. Lax,et al. FRS2 Proteins Recruit Intracellular Signaling Pathways by Binding to Diverse Targets on Fibroblast Growth Factor and Nerve Growth Factor Receptors , 2000, Molecular and Cellular Biology.
[47] S. Barry,et al. AZD2171: a highly potent, orally bioavailable, vascular endothelial growth factor receptor-2 tyrosine kinase inhibitor for the treatment of cancer. , 2005, Cancer research.
[48] S. Tsai,et al. Parallel hybridization analysis of multiple protein kinase genes: identification of gene expression patterns characteristic of human hepatocellular carcinoma. , 1998, Genomics.
[49] E. Madrigal-Bujaidar,et al. Genetic expression profiles and chromosomal alterations in sporadic breast cancer in Mexican women. , 2006, Cancer genetics and cytogenetics.
[50] G. Amann,et al. Analysis of gene amplification and prognostic markers in ovarian cancer using comparative genomic hybridization for microarrays and immunohistochemical analysis for tissue microarrays. , 2006, American journal of clinical pathology.
[51] G. Chang,et al. Macromodel—an integrated software system for modeling organic and bioorganic molecules using molecular mechanics , 1990 .
[52] C. Schoch,et al. The t(8;17)(p11;q23) in the 8p11 myeloproliferative syndrome fuses MYO18A to FGFR1 , 2005, Leukemia.
[53] Yuji Yamamoto,et al. E7080, a novel inhibitor that targets multiple kinases, has potent antitumor activities against stem cell factor producing human small cell lung cancer H146, based on angiogenesis inhibition , 2008, International journal of cancer.